| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2776092 | Journal of the American Society of Cytopathology | 2015 | 6 Pages |
Abstract
EBUS-FNA is a useful diagnostic modality in lung allograft recipients and is of value in confirming and staging thoracic malignancies in this population. Carcinoma subtyping is feasible by EBUS-FNA, and performance of ancillary studies to confirm clonality in post-transplant lymphoproliferative disorders is possible.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Clinical Biochemistry
Authors
Charles D. MD, Jennifer A. MD, Sonali MD, Carol F. MD, Marie M. DO, Peter J. MD, MPH, Fadi W. MD,